NASDAQ : GENB
Generate Biomedicines, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 14.46 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.86B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.86B |
| Enterprise Value | 1.46B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 128.35M |
| Shares Outstanding | 128.35M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +97.68% |
| Owned by Insiders (%) | 4.07% |
| Owned by Institutions (%) | 30.68% |
| Float | 60.45M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 70.08 |
| Forward PS | 92.11 |
| PB Ratio | 4.07 |
| P/TBV Ratio | 4.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 55.17 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 8.30 |
| Quick Ratio | 8.08 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -328.93 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -51.97% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $84,881 |
| Profits Per Employee | -$861,135 |
| Employee Count | 312 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 144,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 15.00 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 52.75 |
| Average Volume (20 Days) | 1,064,469 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 8.93M |
| Short Previous Month | 7.42M |
| Short % of Shares Out | 6.96% |
| Short % of Float | 14.77% |
| Short Ratio (days to cover) | 7.37 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 26.48M |
| Gross Profit | -213.80M |
| Operating Income | -262.49M |
| Pretax Income | -250.73M |
| Net Income | -268.67M |
| EBITDA | -249.55M |
| EBIT | -262.49M |
| Loss Per Share | -$3.28 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 457.42M |
| Total Debt | 62.63M |
| Net Cash | 394.79M |
| Net Cash Per Share | $3.08 |
| Equity (Book Value) | 456.05M |
| Book Value Per Share | 3.56 |
| Working Capital | 413.62M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -237.02M |
| Capital Expenditures | -7.32M |
| Depreciation & Amortization | 12.94M |
| Net Borrowing | -5.21M |
| Free Cash Flow | -244.35M |
| FCF Per Share | -$1.90 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -991.15% |
| Pretax Margin | -946.77% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -22.66% |
| FCF Yield | -13.17% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $27.00 |
| Price Target Difference | 86.72% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 42.47% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 6.99 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |